Overview

A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

Status:
Terminated

Trial end date:
2007-08-01

Target enrollment:
0

Participant gender:
All

Summary

AG-024322 may work in cancer by stopping cancer cells from multiplying. AG-024322 is and intravenous drug from a new class of drugs call cyclin-dependent kinase (CDK inhibitors). This research study is the first time that AG-024322 will be given to people.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Cyclin-Dependent Kinase Inhibitor Proteins

Criteria

Inclusion Criteria:

- Advanced solid tumors or follicular of diffuse large cell non-Hodgkin's lymphoma,
histologically or cytologically proven at diagnosis which is refractory to or
intolerant of established therapy know to provide clinical benefit for their condition

- Adequate blood cell counts, kidney function and liver function and and ECOG score of 0
or 1.

Exclusion Criteria:

- Prior high-dose chemotherapy requiring hemapoietic stem cell rescue

- Previous radiation therapy to >25% of the bone marrow

- Active or unstable cardiac disease or history of heart attack within 6 months